Related Experiment Video
Updated: May 11, 2026

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans
Tilde V Eskildsen1, Pia L Jeppesen, Mikael Schneider
1Department of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, DK-5000 Odense, Denmark. soeren.sheikh@ouh.regionsyddanmark.dk.
Abstract:
MicroRNAs (miRNAs), a group of small non-coding RNAs that fine tune translation of multiple target mRNAs, are emerging as key regulators in cardiovascular development and disease. MiRNAs are involved in cardiac hypertrophy, heart failure and remodeling following cardiac infarction; however, miRNAs involved in hypertension have not been thoroughly investigated. We have recently reported that specific miRNAs play an integral role in Angiotensin II receptor (AT1R) signaling, especially after activation of the Gαq signaling pathway. Since AT1R blockers are widely used to treat hypertension, we undertook a detailed analysis of potential miRNAs involved in Angiotensin II (AngII) mediated hypertension in rats and hypertensive patients, using miRNA microarray and qPCR analysis. The miR-132 and miR-212 are highly increased in the heart, aortic wall and kidney of rats with hypertension (159 ± 12 mm Hg) and cardiac hypertrophy following chronic AngII infusion. In addition, activation of the endothelin receptor, another Gαq coupled receptor, also increased miR-132 and miR-212. We sought to extend these observations using human samples by reasoning that AT1R blockers may decrease miR-132 and miR-212. We analyzed tissue samples of mammary artery obtained from surplus arterial tissue after coronary bypass operations. Indeed, we found a decrease in expression levels of miR-132 and miR-212 in human arteries from bypass-operated patients treated with AT1R blockers, whereas treatment with β-blockers had no effect. Taken together, these data suggest that miR-132 and miR-212 are involved in AngII induced hypertension, providing a new perspective in hypertensive disease mechanisms.
Insights
MicroRNAs miR-132 and miR-212 are elevated in hypertension. Angiotensin II receptor blockers decreased these microRNAs in human arteries, suggesting their role in hypertensive disease mechanisms.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Hypertension Research
Background:
- MicroRNAs (miRNAs) regulate gene expression and are implicated in cardiovascular diseases.
- While miRNAs' roles in cardiac hypertrophy and heart failure are known, their involvement in hypertension requires further investigation.
- Specific miRNAs are integral to Angiotensin II receptor (AT1R) signaling, particularly via the Gαq pathway.
Purpose of the Study:
- To investigate the role of specific miRNAs in Angiotensin II (AngII)-mediated hypertension.
- To analyze miRNA expression in hypertensive rat models and human patients.
- To determine the effect of AT1R blockers on miRNA levels in hypertension.
Main Methods:
- Utilized miRNA microarray and quantitative PCR (qPCR) analysis.
- Examined miRNA expression in the heart, aortic wall, and kidney of hypertensive rats.
- Analyzed miRNA expression in human mammary artery samples from patients treated with AT1R blockers or beta-blockers.
Main Results:
- miR-132 and miR-212 levels were significantly increased in hypertensive rats and in response to AngII infusion and endothelin receptor activation.
- Expression of miR-132 and miR-212 was decreased in human arteries of patients treated with AT1R blockers.
- Beta-blocker treatment did not affect miR-132 and miR-212 expression in human arteries.
Conclusions:
- miR-132 and miR-212 are implicated in Angiotensin II-induced hypertension.
- These findings offer a new perspective on the molecular mechanisms underlying hypertensive disease.
- Targeting miR-132 and miR-212 may represent a novel therapeutic strategy for hypertension.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hormonal Regulation

